Therapeutic role of kaempferol and myricetin in streptozotocin-induced diabetes synergistically via modulation in pancreatic amylase, glycogen storage and insulin secretion

Abstract

Kaempferol and Myricetin alone have promising bene ts on diabetes and related complications, yet the effectiveness of cotreating the two compounds on diabetes have not been studied. The existing investigation was to study the combined anti-diabetic effect of kaempferol and myricetin in streptozotocin (STZ)-activated diabetes in rats. MethodsTo evaluate the antidiabetic activity, 36 Wistar rats were segregated into six groups; Normal, 50 mg/kg STZ-induced diabetes, and four (50 mg/kg kaempferol, 50 mg/kg myricetin, 25mg/kg kaempferol + myricetin, and 5mg/kg glibenclamide) compound-treated diabetic groups. The effects of co-treatment on parameters, glucose, insulin, lipid pro le, liver enzymes, antioxidant biomarkers, and in ammatory cytokines were measured. ResultsThe study revealed that combined treatment restored the assessed parameters including glucose levels, insulin levels, in ammatory cytokines, oxidative markers, and lipid and liver enzymes in diabetic rats. ConclusionThe results indicate that cotreatment of kaempferol and myricetin has bene cial role against diabetes suggesting that cotreatment of these compounds can be used therapeutically in treating diabetes.

Green synthesis of silver nanoparticles (AgNPs) using Alstonia scholaris extract: Evaluation of their antioxidant, enzyme inhibitory, antimicrobial, and antimutagenic activities through in vitro and in silico studies

“…AgNPs. The α-amylase inhibition activity of kampeferol and gallic acid has recently been reported (93,94) Figure 12 shows the interaction of galantamine (std), kaempferol, gallic acid, and vallesamine with BchE. All interact with BchE active sites by conventional hydrogen bonds, carbon − hydrogen bonds, Pi − Pi stacking, and Pi − alkyl interactions.…”

Flavonols as a Potential Pharmacological Intervention for Alleviating Cognitive Decline in Diabetes: Evidence from Preclinical Studies

“…Like quercetin, myricetin (3,3 ,4 ,5,5 ,7-hexahydroxylflavone) is a flavonoid from the flavonol class that is present in various fruits and vegetables, nuts, berries, and beverages [279]. Animal and clinical studies revealed its hypoglycemic effect and ability to increase the sensitivity to insulin and enhance glycogen synthesis and glucose utilization, together with the prominent antioxidative and anti-inflammatory activities that are most likely essential for its protective effects against diabetic complications in various tissues [280][281][282][283][284][285]. Myricetin possesses five hydroxyl groups that underlie its potent antioxidative activity.…”